View clinical trials related to T2DM (Type 2 Diabetes Mellitus).
Filter by:T2DM patient will be recruited from endocrine OPD 1. Clinical History and Examination: 1. General Physical Examination: - Height (cm) - weight (kg) - BMI (kg/m2) - Blood Pressure (mmHg) 2. Anthropometry: Circumferences and skinfold thickness will be recorded for the patients in the following manner. Circumferences: - Waist circumference (cm) - Hip circumference (cm) - Mid-arm circumference (cm) - Mid-thigh circumference (cm) 3. Skin fold thickness: Skin fold thickness will be measured by using (LANGE skin fold calipers) (to nearest of 1 mm) at the following sites - Biceps (mm) - Triceps (mm) - Thigh (mm) - Calf (mm) - Sub scapular (mm) - Supra-iliac (mm) - Anterior axillary fold. (mm) 2. Biochemical Test: The biochemical analysis will be done using ELISA kit or commercially available kits - Blood glucose (mg/dL) - HbA1c (%) - Serum insulin (μIU/mL) - Total Cholestrol (mg/dl) - Triglyceride (mg/dl) - Fructosamine (umol/L) - Adiponectin (µg/ml) -- HOMA-IR 3. Body Composition Analysis (TANITA)
To evaluate the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of single dose of HSK7653 tablets in healthy adult subjects, and to identify the metabolites of HSK7653 in healthy adult subjects
This is a single-center, randomized, double-blind, placebo-controlled, escalating single-dose and multiple-dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HEC88473 injection in healthy subjects, obese subjects and subjects with type 2 diabetes mellitus (T2DM).
A Multi-center, Open-label, Extension study to Evaluate the long term Safety and Efficacy of DWP16001 add-on to metformin in Patients with type 2 diabetes mellitus inadequately controlled on metformin
The purpose of this study is evaluate the long term safety and efficacy of DWP16001 compared to placebo in the treatment of type 2 diabetes mellitus.
This study aimed therefore to evaluate bone density (BD) and OPG levels in the peri-implant crevicular fluid (PICF) in lased controlled type II Diabetes Mellitus (T2DM) patients versus non-lased T2DM patients. 40 T2DM patients were included in this study. Implants were randomly inserted in 20 non-lased T2DM patients (Control) and 20 lased T2DM patients (Intervention). BD and OPG levels in the PICF were assessed in both groups at the follow up points.
To evaluate a pharmacokinetic drug interaction between AJU-A51R1 and AJU-A51R2 in healthy male volunteers.
Previous Icelandic studies regarding prevalence of diabetes have mostly used data from the capital area. Information on the proportion of people at risk at developing T2DM or having undiagnosed T2DM among people living in rural Northern Iceland is unknown. Clinical guidelines recommend that patients with prediabetes (diabetes warning signs) should be referred to a counselling program. The study will evaluate effectiveness of nurse-coordinated Guided Self-Determination (GSD) follow up program toward health promotion, for people at risk of T2DM.
The purpose of this study is to determine the efficacy and safety of DWP16001 compared to active drug in the treatment of type 2 diabetes mellitus.
Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of DWP16001 in Combination with Metformin in Patients With Type 2 Diabetes Mellitus who Have Inadequate Glycemic Control on Metformin Alone.